DOCSLIB.ORG

Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma Zhang Xiao Ying1, Meiyan Jin2, Luke F

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma Zhang Xiao Ying1, Meiyan Jin2, Luke F Published OnlineFirst June 7, 2016; DOI: 10.1158/1078-0432.CCR-16-0609 Biology of Human Tumors Clinical Cancer Research Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma Zhang Xiao Ying1, Meiyan Jin2, Luke F. Peterson1, Denzil Bernard1, Kamlai Saiya-Cork1, Mehmet Yildiz1, Shaomeng Wang1, Mark S. Kaminski1, Alfred E. Chang3, Daniel J. Klionsky2, and Sami N. Malek1 Abstract Purpose: This study was performed to further our understand- Mutations in RRAGC distinctly clustered on one protein surface ing of the biological and genetic basis of follicular lymphoma and area surrounding the GTP/GDP–binding sites. Mutated RRAGC to identify potential novel therapy targets. proteins demonstrated increased binding to RPTOR (raptor) and Experimental Design: We analyzed previously generated substantially decreased interactions with the product of the tumor whole exome sequencing data of 23 follicular lymphoma cases suppressor gene FLCN (folliculin). In stable retrovirally trans- and one transformed follicular lymphoma case and expanded fected 293T cells, cultured in the presence or absence of leucine, findings to a combined total of 125 follicular lymphoma/3 multiple RRAGC mutations demonstrated elevated MTOR acti- transformed follicular lymphoma. We modeled the three- vation as evidenced by increased RPS6KB/S6-kinase phosphory- dimensional location of RRAGC-associated hotspot muta- lation. Similar activation phenotypes were uncovered in yeast tions. We performed functional studies on novel RRAGC engineered to express mutations in the RRAGC homolog Gtr2 and mutants in stable retrovirally transduced HEK293T cells, stable in multiple lymphoma cell lines expressing HA-tagged RRAGC- lentivirally transduced lymphoma cell lines, and in Saccharo- mutant proteins. myces cerevisiae. Conclusions: Our discovery of activating mutations in RRAGC Results: We report recurrent mutations, including multiple in approximately 10% of follicular lymphoma provides the amino acid hotspots, in the small G-protein RRAGC, which is mechanistic rationale to study mutational MTOR activation and part of a protein complex that signals intracellular amino acid MTOR inhibition as a potential novel actionable therapeutic concentrations to MTOR, in 9.4% of follicular lymphoma cases. target in follicular lymphoma. Clin Cancer Res; 1–11. Ó2016 AACR. Introduction Follicular lymphoma has a varied clinical course that is influ- enced by follicular lymphoma tumor cell–intrinsic and cell- Follicular lymphoma constitutes the most common indolent extrinsic deregulations (2, 5, 6, 8–12). Cell-intrinsic factors, B-cell lymphoma, with an incidence and prevalence of approx- including genomic aberrations and epigenetic deregulations, imately 14,000 and approximately 100,000 cases, respectively in prominently influence the follicular lymphoma phenotype. At the United States (1). Follicular lymphoma remains incurable the genomic level, follicular lymphoma is characterized by recur- with conventional therapies and most patients receive multiple rent acquired structural abnormalities, including translocation treatment regimens during the course of their illness. The devel- (14;18) deregulating BCL2 expression, acquired genomic copy opment of targeted follicular lymphoma–directed therapies is in number aberrations (aCNA), and frequent acquired uniparental- early stages (2–7) and lags behind progress made in other lym- disomy (aUPD)/copy neutral LOH (cnLOH; refs. 13–17). Fur- phoproliferative diseases such as chronic lymphocytic leukemia thermore, an expanding group of recurrently mutated genes has (CLL) or mantle cell lymphoma (MCL). recently been shown to underlie the pathogenesis of follicular lymphoma (KMT2D/MLL2, CREBBP, EZH2, EP300, ARID1A, HIST1H1 B-E, STAT6, and others) and some of these afford novel 1Division of Hematology and Oncology, Department of Internal Med- opportunities for targeted therapy developments (18–26). icine, University of Michigan, Ann Arbor, Michigan. 2Life Sciences To further our understanding of the biological and genetic basis 3 Institute, University of Michigan, Ann Arbor, Michigan. Department of follicular lymphoma and to identify targets for novel therapeutic of Surgery, University of Michigan, Ann Arbor, Michigan. approaches, we have further analyzed follicular lymphoma whole Note: Supplementary data for this article are available at Clinical Cancer exome sequencing (WES) data and have identified recurrent muta- Research Online (http://clincancerres.aacrjournals.org/). tions in the MTOR regulator RRAGC, a small G-protein. RRAGC Prior presentation: Presented as part of a podium presentation at the American forms heterodimers with either RRAGA or RRAGB and together Society of Hematology Meeting, Orlando FL, 2015. these dimers are part of a multiprotein complex that under con- Corresponding Author: Sami N. Malek, University of Michigan, 1500 East Medical ditions of amino acid sufficiency facilitates recruitment of MTOR to Center Drive, 4312 Cancer Center, Ann Arbor, MI 48109-0936. Phone: 734-763- lysosomal membranes resulting in MTOR activation through RHEB 2194; Fax: 734-647-9654; E-mail: [email protected] (27–31). Through sequencing of RRAGC in a combined 125 doi: 10.1158/1078-0432.CCR-16-0609 follicular lymphoma/3 transformed follicular lymphoma cases, Ó2016 American Association for Cancer Research. we identified novel RRAGC mutations, including multiple www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 27, 2021. © 2016 American Association for Cancer Research. Published OnlineFirst June 7, 2016; DOI: 10.1158/1078-0432.CCR-16-0609 Ying et al. 3 program (http://primer3.ut.ee/) and sequence information Translational Relevance generated using direct sequencing as described. Mutations were Follicular lymphoma constitutes the second most common confirmed to be somatically acquired using unamplified lympho- non-Hodgkin lymphoma (NHL) in the United States, with ma cell–derived DNA and paired CD3 cell–derived DNA as over 100,000 patients living with the disease. Almost all templates isolated from highly pure flow-sorted cells. patients with follicular lymphoma need therapy within years from diagnosis, and most patients receive multiple chemo- or RRAGC cDNA mutagenesis, retroviral and lentiviral vector immunotherapies over their lifetimes. Despite recent progress, generation, cell transfection, and cell transduction to generate the development of targeted therapies in follicular lymphoma stable cell lines is in its early stages. Here, we report on recurrent activating Reagents and mutagenesis. A pCMV-SPORT plasmid containing mutations in the MTOR regulator RRAGC, a small G-protein the RRAGC cDNA (cat#: MHS6278-202757712; accession: and a component of the cellular amino acid sensing and BC016668) was purchased from Thermo Scientific, and used as sufficiency signaling pathway in approximately 10% of follic- a template to generate mutant RRAGC cDNAs using the Quik- ular lymphoma. Follicular lymphoma–associated RRAGC ChangeLightning Site-Directed Mutagenesis Kit (Stratagene/Agi- mutations activated MTOR as evidenced by elevated phos- lent). Full-length wild-type (WT) and mutant HA-tagged RRAGC phorylated RPS6KB/S6-kinase phosphorylation in multiple were constructed using PCR and cloned into the PacI/NotI sites of experimental systems. These data provide the mechanistic the lentiviral vector FG9 (a gift from Dr. Colin Duckett, University rationale to study mutational MTOR activation in follicular of Michigan; ref. 32). HA-tagged raptor (#8513) and RRAGB WT lymphoma and MTOR inhibition as a potential novel action- (#19301) was purchased from Addgene (27). Anti-HA antibody able therapeutic target in follicular lymphoma subsets. was purchased from Roche (clone 3F10, #11867423001). Anti- raptor (05-1470) was from Millipore. Anti-b-actin (#A544) was from Sigma Aldrich. Antibodies against RRAGC (#3360), anti- folliculin (#3697), anti-RRAGB (#8150), anti-RRAGA (#4357), mutation hotspots, in approximately 10% of follicular lymphoma. anti-S6Kinase (#9202) and anti–pS6-Kinase-Thr 389 (#9205) Detailed functional studies in multiple complementary experimen- were purchased from Cell Signaling Technology. tal systems demonstrated that follicular lymphoma–associated RRAGC mutations are activating MTOR as evidenced by elevated Transient transfection studies in HEK293T cells. HEK293T cells phosphorylated (p)-RPS6KB/S6-kinase (S6K) levels. In aggregate, were transfected in 10-cm dishes with 1 or 2 mg of plasmids these data provide novel insights into the properties of recurrent encoding either WT or mutant forms of RRAGC or various other follicular lymphoma–associated RRAGC mutations and have constructs as indicated using polyethylenimine (Polyscience Inc., implications for novel therapy developments targeting MTOR in #23966). genetically defined follicular lymphoma subsets. Generation of stable transduced HEK293T cell lines. RRAGC cDNAs Materials and Methods excised from pCR Blunt topo vectors using EcoR1 were ligated into Patient characteristics and study source material MSCV-IRES-PURO (MIP; ref. 33) previously dephosphorylated Twenty-three follicular lymphoma cases and one transformed with shrimp alkaline phosphatase (#78390; Affymetrix). Retro- follicular lymphoma provided the source material for massive viral production and infection of cells followed by puromycin parallel sequencing (WES) as described and characteristics of these selection were performed as described previously (33). The cases have been published (18, 22). Results
Load more

Recommended publications
  • Nuclear Organization and the Epigenetic Landscape of the Mus Musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, [email protected]
    University of Connecticut OpenCommons@UConn Doctoral Dissertations University of Connecticut Graduate School 8-9-2019 Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome Alicia Liu University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/dissertations Recommended Citation Liu, Alicia, "Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome" (2019). Doctoral Dissertations. 2273. https://opencommons.uconn.edu/dissertations/2273 Nuclear Organization and the Epigenetic Landscape of the Mus musculus X-Chromosome Alicia J. Liu, Ph.D. University of Connecticut, 2019 ABSTRACT X-linked imprinted genes have been hypothesized to contribute parent-of-origin influences on social cognition. A cluster of imprinted genes Xlr3b, Xlr4b, and Xlr4c, implicated in cognitive defects, are maternally expressed and paternally silent in the murine brain. These genes defy classic mechanisms of autosomal imprinting, suggesting a novel method of imprinted gene regulation. Using Xlr3b and Xlr4c as bait, this study uses 4C-Seq on neonatal whole brain of a 39,XO mouse model, to provide the first in-depth analysis of chromatin dynamics surrounding an imprinted locus on the X-chromosome. Significant differences in long-range contacts exist be- tween XM and XP monosomic samples. In addition, XM interaction profiles contact a greater number of genes linked to cognitive impairment, abnormality of the nervous system, and abnormality of higher mental function. This is not a pattern that is unique to the imprinted Xlr3/4 locus. Additional Alicia J. Liu - University of Connecticut - 2019 4C-Seq experiments show that other genes on the X-chromosome, implicated in intellectual disability and/or ASD, also produce more maternal contacts to other X-linked genes linked to cognitive impairment.
    [Show full text]
  • CD56+ T-Cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients
    CD56+ T-cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients Institute of Infection and Global Health Department of Clinical Infection, Microbiology and Immunology Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Mazen Mohammed Almehmadi December 2014 - 1 - Abstract Human T cells expressing CD56 are capable of tumour cell lysis following activation with interleukin-2 but their role in viral immunity has been less well studied. The work described in this thesis aimed to investigate CD56+ T-cells in relation to cytomegalovirus infection in healthy subjects and kidney transplant patients (KTPs). Proportions of CD56+ T cells were found to be highly significantly increased in healthy cytomegalovirus-seropositive (CMV+) compared to cytomegalovirus-seronegative (CMV-) subjects (8.38% ± 0.33 versus 3.29%± 0.33; P < 0.0001). In donor CMV-/recipient CMV- (D-/R-)- KTPs levels of CD56+ T cells were 1.9% ±0.35 versus 5.42% ±1.01 in D+/R- patients and 5.11% ±0.69 in R+ patients (P 0.0247 and < 0.0001 respectively). CD56+ T cells in both healthy CMV+ subjects and KTPs expressed markers of effector memory- RA T-cells (TEMRA) while in healthy CMV- subjects and D-/R- KTPs the phenotype was predominantly that of naïve T-cells. Other surface markers, CD8, CD4, CD58, CD57, CD94 and NKG2C were expressed by a significantly higher proportion of CD56+ T-cells in healthy CMV+ than CMV- subjects. Functional studies showed levels of pro-inflammatory cytokines IFN-γ and TNF-α, as well as granzyme B and CD107a were significantly higher in CD56+ T-cells from CMV+ than CMV- subjects following stimulation with CMV antigens.
    [Show full text]
  • The Inactive X Chromosome Is Epigenetically Unstable and Transcriptionally Labile in Breast Cancer
    Supplemental Information The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer Ronan Chaligné1,2,3,8, Tatiana Popova1,4, Marco-Antonio Mendoza-Parra5, Mohamed-Ashick M. Saleem5 , David Gentien1,6, Kristen Ban1,2,3,8, Tristan Piolot1,7, Olivier Leroy1,7, Odette Mariani6, Hinrich Gronemeyer*5, Anne Vincent-Salomon*1,4,6,8, Marc-Henri Stern*1,4,6 and Edith Heard*1,2,3,8 Extended Experimental Procedures Cell Culture Human Mammary Epithelial Cells (HMEC, Invitrogen) were grown in serum-free medium (HuMEC, Invitrogen). WI- 38, ZR-75-1, SK-BR-3 and MDA-MB-436 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) containing 10% fetal bovine serum (FBS). DNA Methylation analysis. We bisulfite-treated 2 µg of genomic DNA using Epitect bisulfite kit (Qiagen). Bisulfite converted DNA was amplified with bisulfite primers listed in Table S3. All primers incorporated a T7 promoter tag, and PCR conditions are available upon request. We analyzed PCR products by MALDI-TOF mass spectrometry after in vitro transcription and specific cleavage (EpiTYPER by Sequenom®). For each amplicon, we analyzed two independent DNA samples and several CG sites in the CpG Island. Design of primers and selection of best promoter region to assess (approx. 500 bp) were done by a combination of UCSC Genome Browser (http://genome.ucsc.edu) and MethPrimer (http://www.urogene.org). All the primers used are listed (Table S3). NB: MAGEC2 CpG analysis have been done with a combination of two CpG island identified in the gene core. Analysis of RNA allelic expression profiles (based on Human SNP Array 6.0) DNA and RNA hybridizations were normalized by Genotyping console.
    [Show full text]
  • Euchromatin Histone Methyltransferase II (EHMT2) Regulates the Expression of Ras-Related GTP Binding C (RRAGC) Protein
    BMB Rep. 2020; 53(11): 576-581 BMB www.bmbreports.org Reports Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein Supyong Hwang1, Soyoung Kim1, Kyungkon Kim1,2,3, Jeonghun Yeom2, Sojung Park1 & Inki Kim1,2,3,* 1Biomedical Research Center, ASAN Institute for Life Sciences, ASAN Medical Center, Seoul 05505, 2Convergence Medicine Research Center (CREDIT), ASAN Institute for Life Sciences, ASAN Medical Center, Seoul 05505, 3Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul 05505, Korea Dimethylation of the histone H3 protein at lysine residue 9 INTRODUCTION (H3K9) is mediated by euchromatin histone methyltransferase II (EHMT2) and results in transcriptional repression of target Epigenetic modifications are gene regulatory mechanisms that genes. Recently, chemical inhibition of EHMT2 was shown to are independent of changes in DNA sequences (1). This mode induce various physiological outcomes, including endoplasmic of gene regulation can be achieved by means of histone and reticulum stress-associated genes transcription in cancer cells. DNA modifications, such as methylation and acetylation (1). To identify genes that are transcriptionally repressed by EHMT2 Among these, methylation at lysine residues 4 (H3K4) and 36 during apoptosis, and cell stress responses, we screened genes (H3K36) of histone H3 are hallmarks of transcriptional acti- that are upregulated by BIX-01294, a chemical inhibitor of vation, whereas methylation of histone H3 residues at lysines EHMT2. RNA sequencing analyses revealed 77 genes that were 9 (H3K9) and 27 (H3K27) leads to repression (2). Methylation upregulated by BIX-01294 in all four hepatic cell carcinoma of histones is accomplished by histone methyltransferases (HMTs) (HCC) cell lines.
    [Show full text]
  • Genome-Wide Analysis of Transcriptional Bursting-Induced Noise in Mammalian Cells
    bioRxiv preprint doi: https://doi.org/10.1101/736207; this version posted August 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Genome-wide analysis of transcriptional bursting-induced noise in mammalian cells Authors: Hiroshi Ochiai1*, Tetsutaro Hayashi2, Mana Umeda2, Mika Yoshimura2, Akihito Harada3, Yukiko Shimizu4, Kenta Nakano4, Noriko Saitoh5, Hiroshi Kimura6, Zhe Liu7, Takashi Yamamoto1, Tadashi Okamura4,8, Yasuyuki Ohkawa3, Itoshi Nikaido2,9* Affiliations: 1Graduate School of Integrated Sciences for Life, Hiroshima University, Higashi-Hiroshima, Hiroshima, 739-0046, Japan 2Laboratory for Bioinformatics Research, RIKEN BDR, Wako, Saitama, 351-0198, Japan 3Division of Transcriptomics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Fukuoka, 812-0054, Japan 4Department of Animal Medicine, National Center for Global Health and Medicine (NCGM), Tokyo, 812-0054, Japan 5Division of Cancer Biology, The Cancer Institute of JFCR, Tokyo, 135-8550, Japan 6Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa, 226-8503, Japan 7Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA, 20147, USA 8Section of Animal Models, Department of Infectious Diseases, National Center for Global Health and Medicine (NCGM), Tokyo, 812-0054, Japan 9Bioinformatics Course, Master’s/Doctoral Program in Life Science Innovation (T-LSI), School of Integrative and Global Majors (SIGMA), University of Tsukuba, Wako, 351-0198, Japan *Corresponding authors Corresponding authors e-mail addresses Hiroshi Ochiai, [email protected] Itoshi Nikaido, [email protected] bioRxiv preprint doi: https://doi.org/10.1101/736207; this version posted August 15, 2019.
    [Show full text]
  • Effects of Rapamycin on Social Interaction Deficits and Gene
    Kotajima-Murakami et al. Molecular Brain (2019) 12:3 https://doi.org/10.1186/s13041-018-0423-2 RESEARCH Open Access Effects of rapamycin on social interaction deficits and gene expression in mice exposed to valproic acid in utero Hiroko Kotajima-Murakami1,2, Toshiyuki Kobayashi3, Hirofumi Kashii1,4, Atsushi Sato1,5, Yoko Hagino1, Miho Tanaka1,6, Yasumasa Nishito7, Yukio Takamatsu7, Shigeo Uchino1,2 and Kazutaka Ikeda1* Abstract The mammalian target of rapamycin (mTOR) signaling pathway plays a crucial role in cell metabolism, growth, and proliferation. The overactivation of mTOR has been implicated in the pathogenesis of syndromic autism spectrum disorder (ASD), such as tuberous sclerosis complex (TSC). Treatment with the mTOR inhibitor rapamycin improved social interaction deficits in mouse models of TSC. Prenatal exposure to valproic acid (VPA) increases the incidence of ASD. Rodent pups that are exposed to VPA in utero have been used as an animal model of ASD. Activation of the mTOR signaling pathway was recently observed in rodents that were exposed to VPA in utero, and rapamycin ameliorated social interaction deficits. The present study investigated the effect of rapamycin on social interaction deficits in both adolescence and adulthood, and gene expressions in mice that were exposed to VPA in utero. We subcutaneously injected 600 mg/kg VPA in pregnant mice on gestational day 12.5 and used the pups as a model of ASD. The pups were intraperitoneally injected with rapamycin or an equal volume of vehicle once daily for 2 consecutive days. The social interaction test was conducted in the offspring after the last rapamycin administration at 5–6 weeks of ages (adolescence) or 10–11 weeks of age (adulthood).
    [Show full text]
  • Downloaded from [266]
    Patterns of DNA methylation on the human X chromosome and use in analyzing X-chromosome inactivation by Allison Marie Cotton B.Sc., The University of Guelph, 2005 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in The Faculty of Graduate Studies (Medical Genetics) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2012 © Allison Marie Cotton, 2012 Abstract The process of X-chromosome inactivation achieves dosage compensation between mammalian males and females. In females one X chromosome is transcriptionally silenced through a variety of epigenetic modifications including DNA methylation. Most X-linked genes are subject to X-chromosome inactivation and only expressed from the active X chromosome. On the inactive X chromosome, the CpG island promoters of genes subject to X-chromosome inactivation are methylated in their promoter regions, while genes which escape from X- chromosome inactivation have unmethylated CpG island promoters on both the active and inactive X chromosomes. The first objective of this thesis was to determine if the DNA methylation of CpG island promoters could be used to accurately predict X chromosome inactivation status. The second objective was to use DNA methylation to predict X-chromosome inactivation status in a variety of tissues. A comparison of blood, muscle, kidney and neural tissues revealed tissue-specific X-chromosome inactivation, in which 12% of genes escaped from X-chromosome inactivation in some, but not all, tissues. X-linked DNA methylation analysis of placental tissues predicted four times higher escape from X-chromosome inactivation than in any other tissue. Despite the hypomethylation of repetitive elements on both the X chromosome and the autosomes, no changes were detected in the frequency or intensity of placental Cot-1 holes.
    [Show full text]
  • Regulation of Hematopoietic Activity Involving New Interacting Partners (RRAGC & PSMC2, CKAP4 & MANF and CTR9 & CNTNAP2)
    CellBio, 2020, 9, 123-141 https://www.scirp.org/journal/cellbio ISSN Online: 2325-7792 ISSN Print: 2325-7776 Regulation of Hematopoietic Activity Involving New Interacting Partners (RRAGC & PSMC2, CKAP4 & MANF and CTR9 & CNTNAP2) Swati Sharma1, Gurudutta U. Gangenahalli2*, Upma Singh3 1Department of Pharmacology, All India Institute of Medical Science (AIIMS), New Delhi, India 2Stem Cell & Gene Therapy Research Group, Institute of Nuclear Medicine & Allied Sciences, New Delhi, India 3Department of Applied Chemistry, School of Vocational Studies & Applied Sciences, Gautam Buddha University, Greater Noida, India How to cite this paper: Sharma, S., Gan- Abstract genahalli, G.U. and Singh, U. (2020) Regu- lation of Hematopoietic Activity Involving Hematopoietic stem cells (HSCs) are tissue-specific cells giving rise to all New Interacting Partners (RRAGC & PSMC2, mature blood cell types regulated by a diverse group of hematopoietic cyto- CKAP4 & MANF and CTR9 & CNTNAP2). kines and growth factors that influences the survival & proliferation of early CellBio, 9, 123-141. https://doi.org/10.4236/cellbio.2020.93007 progenitors and differentiation mechanisms by modulating the functional ac- tivities of HSCs. In this study, the functional yet distinctive role of three novel Received: August 13, 2020 combinations of gene pairs RRAGC & PSMC2; CKAP4 & MANF; and CTR9 Accepted: September 27, 2020 & CNTNAP2 have been newly identified. These novel combinations of genes Published: September 30, 2020 were confirmed and expressed in K562 human leukemic cell line in the pres- Copyright © 2020 by author(s) and ence of cytokine combination (IL-3, FLT-3 and SCF) using RT-PCR and Scientific Research Publishing Inc. siRNA-mediated gene knock down strategy.
    [Show full text]
  • 862F50a0ea63c82ca473bf845b5
    Brain region Type Enriched GO annotation Gene symbol AQR, ARMC7, BTBD9, HACL1, KCTD10, KCTD13, LSM6, MT2A, MYBPC1, POLD2, SRPX, TNFAIP1, USP25, EC Common type DNA replication, Protein catabolic process, Transport USP28, ZMYND19 EC Common type Transport KIAA1549, MBD5, MYO5B, RAB11A, RAB11FIP1, RAB11FIP2, RAB11FIP3, RAB11FIP4, RAB11FIP5, REPS1 ACD, BMP2K, C1orf63, CDK13, CLK3, CYLC2, DDX3Y, FOXJ3, GNL3L, GRPEL1, KIAA2022, MACROD2, Cellular component organization, Kinase activity, Localization, EC Common type NANOG, PAK1IP1, PCBP1, PCMT1, PLOD1, PLOD2, POT1, PRPS1L1, RASGEF1C, RBM15B, RPS7, RSBN1L, Response to stimulus, Transcription SALL1, SEC16A, TDRD6, TERF1, TERF2IP, TINF2, YTHDF1, YTHDF3, ZC3HAV1L, ZNF281 AGFG1, AKR1C3, ARIH1, ARIH2, BCL10, BFAR, BIRC2, BIRC3, BIRC6, BIRC7, C9orf89, CADPS2, CNOT4, DDX58, DIABLO, DTX1, DTX3L, DZIP3, EIF4E2, EML4, EPS15, EXTL3, FBXL19, FCHO2, GPR108, HLTF, HPCA, HTRA2, INF2, ISG15, KIAA1107, KIAA1797, LNX2, LOC147791, LRSAM1, LTN1, MAGEL2, MAP3K1, MARCH5, MARCH7, MC1R, MFN1, MGRN1, MID1, MID2, MKRN1, MKRN2, MKRN3, MRAP, MUL1, NAIP, PARP9, PCNP, PDZRN3, PJA2, PLCD4, RBCK1, RLIM, RMND5B, RNF10, RNF103, RNF11, RNF111, RNF114, DNA repair, Apoptosis, Protein catabolic process, Protein EC Common type RNF115, RNF125, RNF126, RNF128, RNF13, RNF130, RNF138, RNF14, RNF144A, RNF150, RNF165, RNF166, metabolic process, Protein modification process RNF167, RNF181, RNF182, RNF25, RNF26, RNF38, RNF4, RNF41, RSPRY1, SGCE, SH3RF2, STRADB, TMBIM6, TMEM189, TOPORS, TRAF7, TRIM2, TRIM25, TRIM26, TRIM27, TRIM32, TRIM35, TRIM39,
    [Show full text]
  • Inhibition of Mitochondrial Complex II in Neuronal Cells Triggers Unique
    www.nature.com/scientificreports OPEN Inhibition of mitochondrial complex II in neuronal cells triggers unique pathways culminating in autophagy with implications for neurodegeneration Sathyanarayanan Ranganayaki1, Neema Jamshidi2, Mohamad Aiyaz3, Santhosh‑Kumar Rashmi4, Narayanappa Gayathri4, Pulleri Kandi Harsha5, Balasundaram Padmanabhan6 & Muchukunte Mukunda Srinivas Bharath7* Mitochondrial dysfunction and neurodegeneration underlie movement disorders such as Parkinson’s disease, Huntington’s disease and Manganism among others. As a corollary, inhibition of mitochondrial complex I (CI) and complex II (CII) by toxins 1‑methyl‑4‑phenylpyridinium (MPP+) and 3‑nitropropionic acid (3‑NPA) respectively, induced degenerative changes noted in such neurodegenerative diseases. We aimed to unravel the down‑stream pathways associated with CII inhibition and compared with CI inhibition and the Manganese (Mn) neurotoxicity. Genome‑wide transcriptomics of N27 neuronal cells exposed to 3‑NPA, compared with MPP+ and Mn revealed varied transcriptomic profle. Along with mitochondrial and synaptic pathways, Autophagy was the predominant pathway diferentially regulated in the 3‑NPA model with implications for neuronal survival. This pathway was unique to 3‑NPA, as substantiated by in silico modelling of the three toxins. Morphological and biochemical validation of autophagy markers in the cell model of 3‑NPA revealed incomplete autophagy mediated by mechanistic Target of Rapamycin Complex 2 (mTORC2) pathway. Interestingly, Brain Derived Neurotrophic Factor
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Rag Proteins Regulate Amino-Acid-Induced Mtorc1 Signalling
    Rag proteins regulate amino-acid-induced mTORC1 signalling The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Sancak, Yasemin, and David M. Sabatini. “Rag Proteins Regulate Amino-acid-induced mTORC1 Signalling.” Biochemical Society Transactions 37.1 (2009) : 289-290. As Published http://dx.doi.org/10.1042/bst0370289 Publisher Biomedical Society Version Final published version Citable link http://hdl.handle.net/1721.1/65577 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. mTOR Signalling, Nutrients and Disease 289 Rag proteins regulate amino-acid-induced mTORC1 signalling Yasemin Sancak*† and David M. Sabatini*†‡1 *Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology Department of Biology, Nine Cambridge Center, Cambridge, MA 02142, U.S.A., †MIT Center for Cancer Research, 77 Massachusetts Avenue, Cambridge, MA 02139, U.S.A., and ‡Broad Institute, Seven Cambridge Center, Cambridge, MA 02142, U.S.A. Abstract The serum- and nutrient-sensitive protein kinase mTOR (mammalian target of rapamycin) is a master regulator of cell growth and survival. The mechanisms through which nutrients regulate mTOR have been one of the major unanswered questions in the mTOR field. Identification of the Rag (Ras-related GTPase) family of GTPases as mediators of amino acid signalling to mTOR is an important step towards our understanding of this mechanism. The mTOR (mammalian target of rapamycin) kinase is to amino acid starvation [30]. This observation suggested an evolutionarily conserved protein that regulates cell that there are additional important players in the amino growth, survival and metabolism.
    [Show full text]